Clinical trials
Phase 2 Myeloproliferative Disorders trials in Canada
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
17 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 1 |
| 2007 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 7 |
| Recruiting | 5 |
| Active, not recruiting | 2 |
| Terminated | 2 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 3 |
| Incyte Corporation | 2 |
| University of Manitoba | 2 |
| Children's Oncology Group | 1 |
| Cogent Biosciences, Inc. | 1 |
| Hoffmann-La Roche | 1 |
| John Mascarenhas | 1 |
| Novartis Pharmaceuticals | 1 |
| Ottawa Hospital Research Institute | 1 |
| PharmaEssentia | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Myeloproliferative Disorders | 17 |
| Leukemia, Myeloid, Acute | 6 |
| Myelodysplastic Syndromes | 6 |
| Hematologic Diseases | 4 |
| Myelodysplastic-Myeloproliferative Diseases | 3 |
| Neoplasms | 3 |
| Polycythemia Vera | 3 |
| Primary Myelofibrosis | 3 |
| Thrombocythemia, Essential | 3 |
| Anemia, Refractory, with Excess of Blasts | 2 |
Trials
Showing 1 to 17 of 17. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.